416 related articles for article (PubMed ID: 19060540)
21. Development of a combined heart and carotid artery transplant model to investigate the impact of acute rejection on cardiac allograft vasculopathy.
Soleimani B; Fu F; Lake P; Shi VC
J Heart Lung Transplant; 2008 Apr; 27(4):450-6. PubMed ID: 18374883
[TBL] [Abstract][Full Text] [Related]
22. Recurrent non-melanoma skin cancer: remission of field cancerization after conversion from calcineurin inhibitor- to proliferation signal inhibitor-based immunosuppression in a cardiac transplant recipient.
Signorell J; Hunziker T; Martinelli M; Koestner SC; Mohacsi PJ
Transplant Proc; 2010 Nov; 42(9):3871-5. PubMed ID: 21094874
[TBL] [Abstract][Full Text] [Related]
23. Immunology insights into cardiac allograft rejection.
Savasta M; Lentini S
Rev Cardiovasc Med; 2011; 12(2):e68-76. PubMed ID: 21796085
[TBL] [Abstract][Full Text] [Related]
24. Avoidance of calcineurin inhibitors with use of proliferation signal inhibitors in de novo heart transplantation with renal failure.
González-Vílchez F; de Prada JA; Exposito V; García-Camarero T; Fernández-Friera L; Llano M; Ruano J; Martín-Durán R
J Heart Lung Transplant; 2008 Oct; 27(10):1135-41. PubMed ID: 18926406
[TBL] [Abstract][Full Text] [Related]
25. New advances in antirejection therapy.
Chan M; Pearson GJ
Curr Opin Cardiol; 2007 Mar; 22(2):117-22. PubMed ID: 17284990
[TBL] [Abstract][Full Text] [Related]
26. Prevention of cardiac allograft vasculopathy with Certican (everolimus): the Stanford University experience within the Certican Phase III clinical trial.
Valantine H
J Heart Lung Transplant; 2005 Apr; 24(4 Suppl):S191-5; discussion S210-1. PubMed ID: 15774321
[TBL] [Abstract][Full Text] [Related]
27. Long-term cardiovascular risk in transplantation--insights from the use of everolimus in heart transplantation.
Eisen H
Nephrol Dial Transplant; 2006 Jul; 21 Suppl 3():iii9-13. PubMed ID: 16815858
[TBL] [Abstract][Full Text] [Related]
28. Cardiac allograft vasculopathy: current concepts and treatment.
Waller J; Brook NR; Nicholson ML
Transpl Int; 2003 Jun; 16(6):367-75. PubMed ID: 12756523
[TBL] [Abstract][Full Text] [Related]
29. Is the malononitrilamide FK778 better for the prevention of acute or chronic rejection?
Deuse T; Schrepfer S; Pelletier MP; Fischbein MP; Robbins RC; Reichenspurner H
Transplant Proc; 2007 Mar; 39(2):569-72. PubMed ID: 17362784
[TBL] [Abstract][Full Text] [Related]
30. Sirolimus as primary immunosuppression is associated with improved coronary vasomotor function compared with calcineurin inhibitors in stable cardiac transplant recipients.
Raichlin E; Prasad A; Kremers WK; Edwards BS; Rihal CS; Lerman A; Kushwaha SS
Eur Heart J; 2009 Jun; 30(11):1356-63. PubMed ID: 19383734
[TBL] [Abstract][Full Text] [Related]
31. The University of California at Los Angeles heart transplantation experience.
Kobashigawa JA; Laks H; Wu G; Patel J; Moriguchi J; Hamilton M; Fonarow G; Fishbein M; Ardehali A
Clin Transpl; 2005; ():173-85. PubMed ID: 17424734
[TBL] [Abstract][Full Text] [Related]
32. Chronic allograft dysfunction: can we use mammalian target of rapamycin inhibitors to replace calcineurin inhibitors to preserve graft function?
Wali RK; Weir MR
Curr Opin Organ Transplant; 2008 Dec; 13(6):614-21. PubMed ID: 19060552
[TBL] [Abstract][Full Text] [Related]
33. Everolimus (certican) in heart transplantation: optimizing renal function through minimizing cyclosporine exposure.
Lehmkuhl H; Ross H; Eisen H; Valantine H
Transplant Proc; 2005 Dec; 37(10):4145-9. PubMed ID: 16387066
[TBL] [Abstract][Full Text] [Related]
34. Cardiac allograft vasculopathy: recent developments.
Schmauss D; Weis M
Circulation; 2008 Apr; 117(16):2131-41. PubMed ID: 18427143
[TBL] [Abstract][Full Text] [Related]
35. C. sinensis ablates allograft vasculopathy when used as an adjuvant therapy with cyclosporin A.
Jordan JL; Hirsch GM; Lee TD
Transpl Immunol; 2008 Jul; 19(3-4):159-66. PubMed ID: 18619544
[TBL] [Abstract][Full Text] [Related]
36. Free bone graft attenuates acute rejection and in combination with cyclosporin a leads to indefinite cardiac allograft survival.
Wang H; Ge W; Arp J; Zassoko R; Liu W; Ichim TE; Jiang J; Jevnikar AM; Garcia B
J Immunol; 2009 May; 182(10):5970-81. PubMed ID: 19414748
[TBL] [Abstract][Full Text] [Related]
37. Effect of Everolimus Initiation and Calcineurin Inhibitor Elimination on Cardiac Allograft Vasculopathy in De Novo Heart Transplant Recipients.
Arora S; Andreassen AK; Karason K; Gustafsson F; Eiskjær H; Bøtker HE; Rådegran G; Gude E; Ioanes D; Solbu D; Dellgren G; Ueland T; Aukrust P; Gullestad L;
Circ Heart Fail; 2018 Sep; 11(9):e004050. PubMed ID: 30354362
[TBL] [Abstract][Full Text] [Related]
38. Clinical recommendations for the use of everolimus in heart transplantation.
Manito N; Delgado JF; Crespo-Leiro MG; González-Vílchez F; Almenar L; Arizón JM; Díaz B; Fernández-Yáñez J; Mirabet S; Palomo J; Rodríguez Lambert JL; Roig E; Segovia J
Transplant Rev (Orlando); 2010 Jul; 24(3):129-42. PubMed ID: 20619801
[TBL] [Abstract][Full Text] [Related]
39. Potential role of proliferation signal inhibitors on atherosclerosis in renal transplant patients.
Andrés V; Castro C; Campistol JM
Nephrol Dial Transplant; 2006 Jul; 21 Suppl 3():iii14-7. PubMed ID: 16815851
[TBL] [Abstract][Full Text] [Related]
40. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients.
Eisen HJ; Tuzcu EM; Dorent R; Kobashigawa J; Mancini D; Valantine-von Kaeppler HA; Starling RC; Sørensen K; Hummel M; Lind JM; Abeywickrama KH; Bernhardt P;
N Engl J Med; 2003 Aug; 349(9):847-58. PubMed ID: 12944570
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
